The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Alpha 1 Antitrypsin Deficiency Treatment Market 2024 by Company, Regions, Type and Application, Forecast to 2028
Synopsis
The Alpha 1 Antitrypsin Deficiency Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Alpha 1 Antitrypsin Deficiency Treatment market size is estimated to be worth US$ 1914.5 million in 2021 and is forecast to a readjusted size of USD 3413.7 million by 2028 with a CAGR of 8.6% during review period. COPD accounting for % of the Alpha 1 Antitrypsin Deficiency Treatment global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Augmentation Therapy segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Alpha 1 Antitrypsin Deficiency Treatment include Pfizer, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, and Teva Pharmaceutical Industries, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Alpha 1 Antitrypsin Deficiency Treatment market is split by Indication and by End Users. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Indication and by End Users. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Indication, covers
Augmentation Therapy
Cystic Fibrosis(CF)
Non-CF Bronchiectasis(NCFB)
Diabetes
Other
Market segment by End Users, can be divided into
COPD
Cystic Fibrosis(CF)
Non-CF Bronchiectasis(NCFB)
Diabetes
Market segment by players, this report covers
Pfizer
GlaxoSmithKline
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceutical Industries
Takeda
Baxter
Grifols
CSL Behring
Kamada Ltd
Chiesi Pharmaceuticals
Kedrion Group
Vertex Pharmaceuticals
ProMetic Life Sciences
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Alpha 1 Antitrypsin Deficiency Treatment product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Alpha 1 Antitrypsin Deficiency Treatment, with revenue, gross margin and global market share of Alpha 1 Antitrypsin Deficiency Treatment from 2019 to 2022.
Chapter 3, the Alpha 1 Antitrypsin Deficiency Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Indication and application, with revenue and growth rate by Indication, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Alpha 1 Antitrypsin Deficiency Treatment market forecast, by regions, indication and end users, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Alpha 1 Antitrypsin Deficiency Treatment research findings and conclusion, appendix and data source.
Geographical Area
Global
The Alpha 1 Antitrypsin Deficiency Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Alpha 1 Antitrypsin Deficiency Treatment market size is estimated to be worth US$ 1914.5 million in 2021 and is forecast to a readjusted size of USD 3413.7 million by 2028 with a CAGR of 8.6% during review period. COPD accounting for % of the Alpha 1 Antitrypsin Deficiency Treatment global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Augmentation Therapy segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Alpha 1 Antitrypsin Deficiency Treatment include Pfizer, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, and Teva Pharmaceutical Industries, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Alpha 1 Antitrypsin Deficiency Treatment market is split by Indication and by End Users. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Indication and by End Users. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Indication, covers
Augmentation Therapy
Cystic Fibrosis(CF)
Non-CF Bronchiectasis(NCFB)
Diabetes
Other
Market segment by End Users, can be divided into
COPD
Cystic Fibrosis(CF)
Non-CF Bronchiectasis(NCFB)
Diabetes
Market segment by players, this report covers
Pfizer
GlaxoSmithKline
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceutical Industries
Takeda
Baxter
Grifols
CSL Behring
Kamada Ltd
Chiesi Pharmaceuticals
Kedrion Group
Vertex Pharmaceuticals
ProMetic Life Sciences
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Alpha 1 Antitrypsin Deficiency Treatment product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Alpha 1 Antitrypsin Deficiency Treatment, with revenue, gross margin and global market share of Alpha 1 Antitrypsin Deficiency Treatment from 2019 to 2022.
Chapter 3, the Alpha 1 Antitrypsin Deficiency Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Indication and application, with revenue and growth rate by Indication, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Alpha 1 Antitrypsin Deficiency Treatment market forecast, by regions, indication and end users, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Alpha 1 Antitrypsin Deficiency Treatment research findings and conclusion, appendix and data source.
Geographical Area
Global
Index1 Market Overview
1.1 Product Overview and Scope of Alpha 1 Antitrypsin Deficiency Treatment
1.2 Classification of Alpha 1 Antitrypsin Deficiency Treatment by Indication
1.2.1 Overview: Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication: 2017 Versus 2021 Versus 2028
1.2.2 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Indication in 2021
1.2.3 Augmentation Therapy
1.2.4 Cystic Fibrosis(CF)
1.2.5 Non-CF Bronchiectasis(NCFB)
1.2.6 Diabetes
1.2.7 Other
1.3 Global Alpha 1 Antitrypsin Deficiency Treatment Market by End Users
1.3.1 Overview: Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users: 2017 Versus 2021 Versus 2028
1.3.2 COPD
1.3.3 Cystic Fibrosis(CF)
1.3.4 Non-CF Bronchiectasis(NCFB)
1.3.5 Diabetes
1.4 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size & Forecast
1.5 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast by Region
1.5.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region, (2017-2022)
1.5.3 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size and Prospect (2017-2028)
1.5.4 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size and Prospect (2017-2028)
1.5.6 South America Alpha 1 Antitrypsin Deficiency Treatment Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Alpha 1 Antitrypsin Deficiency Treatment Market Drivers
1.6.2 Alpha 1 Antitrypsin Deficiency Treatment Market Restraints
1.6.3 Alpha 1 Antitrypsin Deficiency Treatment Trends Analysis
2 Company Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.1.4 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Pfizer Recent Developments and Future Plans
2.2 GlaxoSmithKline
2.2.1 GlaxoSmithKline Details
2.2.2 GlaxoSmithKline Major Business
2.2.3 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.2.4 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 GlaxoSmithKline Recent Developments and Future Plans
2.3 AstraZeneca
2.3.1 AstraZeneca Details
2.3.2 AstraZeneca Major Business
2.3.3 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.3.4 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 AstraZeneca Recent Developments and Future Plans
2.4 Boehringer Ingelheim
2.4.1 Boehringer Ingelheim Details
2.4.2 Boehringer Ingelheim Major Business
2.4.3 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.4.4 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Boehringer Ingelheim Recent Developments and Future Plans
2.5 Teva Pharmaceutical Industries
2.5.1 Teva Pharmaceutical Industries Details
2.5.2 Teva Pharmaceutical Industries Major Business
2.5.3 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.5.4 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Teva Pharmaceutical Industries Recent Developments and Future Plans
2.6 Takeda
2.6.1 Takeda Details
2.6.2 Takeda Major Business
2.6.3 Takeda Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.6.4 Takeda Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Takeda Recent Developments and Future Plans
2.7 Baxter
2.7.1 Baxter Details
2.7.2 Baxter Major Business
2.7.3 Baxter Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.7.4 Baxter Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Baxter Recent Developments and Future Plans
2.8 Grifols
2.8.1 Grifols Details
2.8.2 Grifols Major Business
2.8.3 Grifols Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.8.4 Grifols Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Grifols Recent Developments and Future Plans
2.9 CSL Behring
2.9.1 CSL Behring Details
2.9.2 CSL Behring Major Business
2.9.3 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.9.4 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 CSL Behring Recent Developments and Future Plans
2.10 Kamada Ltd
2.10.1 Kamada Ltd Details
2.10.2 Kamada Ltd Major Business
2.10.3 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.10.4 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 Kamada Ltd Recent Developments and Future Plans
2.11 Chiesi Pharmaceuticals
2.11.1 Chiesi Pharmaceuticals Details
2.11.2 Chiesi Pharmaceuticals Major Business
2.11.3 Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.11.4 Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11.5 Chiesi Pharmaceuticals Recent Developments and Future Plans
2.12 Kedrion Group
2.12.1 Kedrion Group Details
2.12.2 Kedrion Group Major Business
2.12.3 Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.12.4 Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12.5 Kedrion Group Recent Developments and Future Plans
2.13 Vertex Pharmaceuticals
2.13.1 Vertex Pharmaceuticals Details
2.13.2 Vertex Pharmaceuticals Major Business
2.13.3 Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.13.4 Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13.5 Vertex Pharmaceuticals Recent Developments and Future Plans
2.14 ProMetic Life Sciences
2.14.1 ProMetic Life Sciences Details
2.14.2 ProMetic Life Sciences Major Business
2.14.3 ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
2.14.4 ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14.5 ProMetic Life Sciences Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Alpha 1 Antitrypsin Deficiency Treatment Players Market Share in 2021
3.2.2 Top 10 Alpha 1 Antitrypsin Deficiency Treatment Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Alpha 1 Antitrypsin Deficiency Treatment Players Head Office, Products and Services Provided
3.4 Alpha 1 Antitrypsin Deficiency Treatment Mergers & Acquisitions
3.5 Alpha 1 Antitrypsin Deficiency Treatment New Entrants and Expansion Plans
4 Market Size Segment by Indication
4.1 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue and Market Share by Indication (2017-2022)
4.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Forecast by Indication (2023-2028)
5 Market Size Segment by End Users
5.1 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by End Users (2017-2022)
5.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Forecast by End Users (2023-2028)
6 North America by Country, by Indication, and by End Users
6.1 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2017-2028)
6.2 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2017-2028)
6.3 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country
6.3.1 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2017-2028)
6.3.2 United States Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)
6.3.3 Canada Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)
6.3.4 Mexico Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)
7 Europe by Country, by Indication, and by End Users
7.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2017-2028)
7.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2017-2028)
7.3 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country
7.3.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2017-2028)
7.3.2 Germany Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)
7.3.3 France Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)
7.3.5 Russia Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)
7.3.6 Italy Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Indication, and by End Users
8.1 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2017-2028)
8.2 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2017-2028)
8.3 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region
8.3.1 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue by Region (2017-2028)
8.3.2 China Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)
8.3.3 Japan Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)
8.3.4 South Korea Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)
8.3.5 India Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)
8.3.7 Australia Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)
9 South America by Country, by Indication, and by End Users
9.1 South America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2017-2028)
9.2 South America Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2017-2028)
9.3 South America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country
9.3.1 South America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2017-2028)
9.3.2 Brazil Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)
9.3.3 Argentina Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Indication, and by End Users
10.1 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2017-2028)
10.2 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2017-2028)
10.3 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country
10.3.1 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2017-2028)
10.3.2 Turkey Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)
10.3.4 UAE Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of TablesList of Tables
Table 1. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million) by Region (2017-2022)
Table 5. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Region (2023-2028)
Table 6. Pfizer Corporate Information, Head Office, and Major Competitors
Table 7. Pfizer Major Business
Table 8. Pfizer Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 9. Pfizer Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors
Table 11. GlaxoSmithKline Major Business
Table 12. GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 13. GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 15. AstraZeneca Major Business
Table 16. AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 17. AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Boehringer Ingelheim Corporate Information, Head Office, and Major Competitors
Table 19. Boehringer Ingelheim Major Business
Table 20. Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 21. Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Teva Pharmaceutical Industries Corporate Information, Head Office, and Major Competitors
Table 23. Teva Pharmaceutical Industries Major Business
Table 24. Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 25. Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Takeda Corporate Information, Head Office, and Major Competitors
Table 27. Takeda Major Business
Table 28. Takeda Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 29. Takeda Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Baxter Corporate Information, Head Office, and Major Competitors
Table 31. Baxter Major Business
Table 32. Baxter Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 33. Baxter Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Grifols Corporate Information, Head Office, and Major Competitors
Table 35. Grifols Major Business
Table 36. Grifols Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 37. Grifols Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. CSL Behring Corporate Information, Head Office, and Major Competitors
Table 39. CSL Behring Major Business
Table 40. CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 41. CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Kamada Ltd Corporate Information, Head Office, and Major Competitors
Table 43. Kamada Ltd Major Business
Table 44. Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 45. Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. Chiesi Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 47. Chiesi Pharmaceuticals Major Business
Table 48. Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 49. Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 50. Kedrion Group Corporate Information, Head Office, and Major Competitors
Table 51. Kedrion Group Major Business
Table 52. Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 53. Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 54. Vertex Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 55. Vertex Pharmaceuticals Major Business
Table 56. Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 57. Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 58. ProMetic Life Sciences Corporate Information, Head Office, and Major Competitors
Table 59. ProMetic Life Sciences Major Business
Table 60. ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 61. ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 62. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 63. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 64. Breakdown of Alpha 1 Antitrypsin Deficiency Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 65. Alpha 1 Antitrypsin Deficiency Treatment Players Head Office, Products and Services Provided
Table 66. Alpha 1 Antitrypsin Deficiency Treatment Mergers & Acquisitions in the Past Five Years
Table 67. Alpha 1 Antitrypsin Deficiency Treatment New Entrants and Expansion Plans
Table 68. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million) by Indication (2017-2022)
Table 69. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Indication (2017-2022)
Table 70. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Forecast by Indication (2023-2028)
Table 71. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2017-2022)
Table 72. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Forecast by End Users (2023-2028)
Table 73. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2017-2022) & (USD Million)
Table 74. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2023-2028) & (USD Million)
Table 75. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2017-2022) & (USD Million)
Table 76. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2023-2028) & (USD Million)
Table 77. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2017-2022) & (USD Million)
Table 78. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2023-2028) & (USD Million)
Table 79. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2017-2022) & (USD Million)
Table 80. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2023-2028) & (USD Million)
Table 81. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2017-2022) & (USD Million)
Table 82. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2023-2028) & (USD Million)
Table 83. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2017-2022) & (USD Million)
Table 84. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2023-2028) & (USD Million)
Table 85. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2017-2022) & (USD Million)
Table 86. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2023-2028) & (USD Million)
Table 87. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2017-2022) & (USD Million)
Table 88. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2023-2028) & (USD Million)
Table 89. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue by Region (2017-2022) & (USD Million)
Table 90. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue by Region (2023-2028) & (USD Million)
Table 91. South America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2017-2022) & (USD Million)
Table 92. South America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2023-2028) & (USD Million)
Table 93. South America Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2017-2022) & (USD Million)
Table 94. South America Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2023-2028) & (USD Million)
Table 95. South America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2017-2022) & (USD Million)
Table 96. South America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2023-2028) & (USD Million)
Table 97. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2017-2022) & (USD Million)
Table 98. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2023-2028) & (USD Million)
Table 99. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2017-2022) & (USD Million)
Table 100. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2023-2028) & (USD Million)
Table 101. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2017-2022) & (USD Million)
Table 102. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Alpha 1 Antitrypsin Deficiency Treatment Picture
Figure 2. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Indication in 2021
Figure 3. Augmentation Therapy
Figure 4. Cystic Fibrosis(CF)
Figure 5. Non-CF Bronchiectasis(NCFB)
Figure 6. Diabetes
Figure 7. Other
Figure 8. Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by End Users in 2021
Figure 9. COPD Picture
Figure 10. Cystic Fibrosis(CF) Picture
Figure 11. Non-CF Bronchiectasis(NCFB) Picture
Figure 12. Diabetes Picture
Figure 13. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 14. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue and Forecast (2017-2028) & (USD Million)
Figure 15. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Region (2017-2028)
Figure 16. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Region in 2021
Figure 17. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 19. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 20. South America Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 21. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 22. Alpha 1 Antitrypsin Deficiency Treatment Market Drivers
Figure 23. Alpha 1 Antitrypsin Deficiency Treatment Market Restraints
Figure 24. Alpha 1 Antitrypsin Deficiency Treatment Market Trends
Figure 25. Pfizer Recent Developments and Future Plans
Figure 26. GlaxoSmithKline Recent Developments and Future Plans
Figure 27. AstraZeneca Recent Developments and Future Plans
Figure 28. Boehringer Ingelheim Recent Developments and Future Plans
Figure 29. Teva Pharmaceutical Industries Recent Developments and Future Plans
Figure 30. Takeda Recent Developments and Future Plans
Figure 31. Baxter Recent Developments and Future Plans
Figure 32. Grifols Recent Developments and Future Plans
Figure 33. CSL Behring Recent Developments and Future Plans
Figure 34. Kamada Ltd Recent Developments and Future Plans
Figure 35. Chiesi Pharmaceuticals Recent Developments and Future Plans
Figure 36. Kedrion Group Recent Developments and Future Plans
Figure 37. Vertex Pharmaceuticals Recent Developments and Future Plans
Figure 38. ProMetic Life Sciences Recent Developments and Future Plans
Figure 39. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Players in 2021
Figure 40. Alpha 1 Antitrypsin Deficiency Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 41. Global Top 3 Players Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share in 2021
Figure 42. Global Top 10 Players Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share in 2021
Figure 43. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 44. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Indication in 2021
Figure 45. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share Forecast by Indication (2023-2028)
Figure 46. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by End Users in 2021
Figure 47. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share Forecast by End Users (2023-2028)
Figure 48. North America Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Indication (2017-2028)
Figure 49. North America Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by End Users (2017-2028)
Figure 50. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Country (2017-2028)
Figure 51. United States Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Canada Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Mexico Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Europe Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Indication (2017-2028)
Figure 55. Europe Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by End Users (2017-2028)
Figure 56. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Country (2017-2028)
Figure 57. Germany Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. France Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. United Kingdom Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Russia Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Italy Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Indication (2017-2028)
Figure 63. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by End Users (2017-2028)
Figure 64. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Region (2017-2028)
Figure 65. China Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Japan Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. South Korea Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. India Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Australia Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. South America Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Indication (2017-2028)
Figure 72. South America Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by End Users (2017-2028)
Figure 73. South America Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Country (2017-2028)
Figure 74. Brazil Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Argentina Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by Indication (2017-2028)
Figure 77. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Sales Market Share by End Users (2017-2028)
Figure 78. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Country (2017-2028)
Figure 79. Turkey Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 80. Saudi Arabia Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 81. UAE Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 82. Methodology
Figure 83. Research Process and Data Source
Published By : GlobalInfoResearch
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
